Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

Overview of attention for article published in Frontiers in immunology, November 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 2 news outlets

twitter: 6 X users

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 72 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 38,428 followers.

RT @FrontImmunol: New Research: Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase…

14 Dec 2020

Reply Repost Favourite

Congratulations to colegues for a nice paper 🎉

14 Dec 2020

Reply Repost Favourite

New Research: Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial: Background Immune checkpoint blockade with monoclonal antibodies targeting programmed death 1… https://t.co/0D

14 Dec 2020

Reply Repost Favourite

RT @ACIR_org: 🎯 Targeting PD-L1 with a vaccine: an initial human safety and immunogenicity study https://t.co/HgcQLEyuiS https://t.co/pQ1xt…

13 Dec 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.